# IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

> **NCT07415525** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer
- Borderline Resectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** IBI343

## Key facts

- **NCT ID:** NCT07415525
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415525, "IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07415525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*